Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.

ABSTRACT: Androgen receptor (AR), is a transcription factor and a member of a hormone receptor superfamily. AR plays a vital role in the progression of prostate cancer and is a crucial target for therapeutic interventions. While the majority of advanced-stage prostate cancer patients will initially respond to the androgen deprivation, the disease often progresses to castrate-resistant prostate cancer (CRPC). Interestingly, CRPC tumors continue to depend on hyperactive AR signaling and will respond to potent second-line antiandrogen therapies, including bicalutamide (CASODEX^®) and enzalutamide (XTANDI^®). However, the progression-free survival rate for the CRPC patients on antiandrogen therapies is only 8-19 months. Hence, there is a need to understand the mechanisms underlying C

SUBMITTER: Shah K 

PROVIDER: S-EPMC7515832 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature